The Effect of Bevacizumab on the Trabeculectomy
- Sponsor
- Samsung Medical Center
- Study ID
- NCT01122966
- Phase
- PHASE2/PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- intraocular injections of bevacizumab — DRUGintracameral and subconjunctival injections
Study Details
The investigators plan to evaluate the additive effect of intracameral and subconjunctival injections of bevacizumab in trabeculectomies with other antimetabolites.
Key Dates
- First listed
- May 13, 2010
- Start date
- Mar 31, 2010
- Status verified
- May 2010
- Primary completion
- Mar 31, 2011
- Completion
- Mar 31, 2012
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: trabeculectomySubjects who have trabeculectomies with intraocular bevacizumab injection
Primary Outcome Measure
intraocular pressure [ Time Frame: on postoperative 1month ]
Central Contacts
- Changwon Kee, M.D., Ph.D.82-2-3410-3564
- Wool Suh, M.D.82-2-3410-3564
Related Studies
- Novel Glaucoma DiagnosticsRecruiting · Wills Eye · Philadelphia, Pennsylvania
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut
- Village-Integrated Eye Worker Trial IIRecruiting · University of California, San Francisco · San Francisco, California
- Pilocarpine Use After Kahook GoniotomyPHASE3 · Recruiting · Montefiore Medical Center · The Bronx, New York